A Decade of Effective Dry Eye Disease Management with Systane Ultra (Polyethylene Glycol/Propylene Glycol with Hydroxypropyl Guar) Lubricant Eye Drops
Sruthi Srinivasan,Venkiteshwar Manoj
DOI: https://doi.org/10.2147/OPTH.S294427
2021-06-10
Clinical Ophthalmology
Abstract:Sruthi Srinivasan, Venkiteshwar Manoj Clinical Development and Medical Affairs, Alcon Research, LLC, Johns Creek, GA, USA Correspondence: Sruthi Srinivasan Clinical Development and Medical Affairs, Alcon Research, LLC, 11460 Johns Creek Parkway, Johns Creek, GA, 30097, USA Tel +1 678 415-5315 Email Dry eye disease (DED) is a multifactorial ocular condition characterized by a loss of homeostasis of the tear film resulting in ocular symptoms of discomfort, irritation, and visual disturbance, all of which significantly impact the patients' social and occupational quality of life. While management of DED depends on the severity of symptoms and signs, use of artificial tear products (ATPs) that replace or supplement the deficient natural tear film is the mainstay treatment option. In this review, we present a decade of evidence on Systane Ultra ® (polyethylene glycol [PEG]/propylene glycol [PG] with hydroxypropyl guar [HP guar]) in effectively managing DED. The active demulcents in Systane Ultra ® —PEG, PG, along with HP guar gelling technology—provide optimal ocular surface protection and lubrication to heal damaged areas of the cornea caused by DED and, therefore, are recommended for patients with both aqueous and/or mucin layer deficiencies. Over the years, several clinical studies have shown that PEG/PG with HP guar provides long-lasting relief from dry eye and has often been chosen as a standard or comparator against other ATPs. Here, we describe the salient features of PEG/PG with HP guar—its constituents and their mechanisms of action. Furthermore, we summarize results from a systematic literature search that identified 23 relevant publications further emphasizing on the effectiveness and safety of PEG/PG with HP guar in alleviating the signs and symptoms of DED. Keywords: artificial tear products, dry eye disease, PEG/PG with HP guar Dry eye disease (DED), also known as keratoconjunctivitis sicca, is a critical and significant public health issue affecting ~344 million people worldwide and more than 30 million in the United States alone [ https://www.tfosdewsreport.org/ , last accessed 10 February 2020]. The estimated prevalence of DED ranges from 5% to 34% in individuals over 50 years old and is more common in women; however, with increased use of electronic/media devices the risk of DED in the younger population is on the rise. 1 , 2 In 2017, the Tear Film & Ocular Surface Society's Dry Eye Workshop II (TFOS DEWS II) report defined DED as a "multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface". It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface. 3 , 4 Patients with DED may complain of ocular discomfort including redness, burning and stinging, ocular dryness, photophobia, foreign body sensation, grittiness, and visual disturbance, all of which significantly affect the quality of lives of patients (reporting up to 34% impairment in daily activities). 5 , 6 Etiologically, DED is classified into (i) aqueous-tear deficiency, characterized by lack of tear secretion from the lacrimal glands, and (ii) evaporative DED, involving excessive evaporative loss of tears due to meibomian gland deficiencies. 2 However, most DED (>80%) are mixed conditions characterized by both lacrimal and meibomian gland deficiencies. 7 With the increasing burden of DED and its impact on patients' daily and social lives that worsens with age, it is important to manage this condition appropriately. 4 Depending on severity of the disease, the treatment and management of DED include patient education (about the condition, management, and prognosis); modifications in the environmental, dietary, and lifestyle-related factors; artificial tear substitutes; punctal plugs; lid warming and intranasal stimulation devices; topical and/or systemic anti-inflammatory medications, such as cyclosporine, diquafosol, and lifitegrast; and surgery. 8 Treatment goals include relieving the signs and symptoms of the disease, improving patients' comfort, re-establishing ocular surface homeostasis, and minimizing corneal damage. 7 , 9 Irrespective of the severity grade of DED, over-the-counter (OTC) eye drops, or artificial tear products (ATPs) are the mainstay and first-line treatment for DED providing immediate symptomatic relief. <a href="#cit0 -Abstract Truncated-